Anthem Biosciences Ltd Q2FY26 – India’s Science Factory Prints Money Faster Than It Prints Molecules
1. At a Glance
Ladies and gentlemen, meet Anthem Biosciences Ltd, the newest shiny biotech kid on Dalal Street that’s managed to turn petri dishes into profit machines. Listed in July 2025, this Bengaluru-based CRDMO star is trading at ₹697 with a market cap of ₹39,119 crore, and an eyebrow-raising P/E of 84.5 — yes, it’s priced like it’s already discovered the next Ozempic.
In Q2FY26, Anthem clocked ₹5,500 million (₹550 crore) in revenue and ₹1,734 million (₹173 crore) in PAT. That’s a YoY growth of 7.1% in profit, while keeping its EBITDA margin at a juicy 40%. For a company that literally manufactures science, the numbers are as sterile as its lab floors.
With ROE at 20.8%, ROCE at 28.5%, and debt/equity at a peaceful 0.05, Anthem is what you get when a scientist marries a chartered accountant. But wait — its EV/EBITDA of 51.4 suggests investors are already paying biotech prices for biotech dreams.
So, is Anthem a real bio-revolution or just another lab-coated love story? Let’s disinfect the data.
2. Introduction
Anthem Biosciences has quietly evolved from a contract research lab to a multi-modal CRDMO powerhouse, blending small molecule chemistry with large molecule biology — a combination as rare as finding punctual approvals in Indian pharma.
Founded in 2006, Anthem’s journey is a masterclass in turning complexity into scale. Think of it as India’s version of Thermo Fisher meets Syngene, but with better humour and lesser corporate suits.
2025 was a blockbuster year for Anthem — IPO done, profits up, and the biotech crowd drooling over its ADCs (Antibody Drug Conjugates) and RNAi platforms. The company now runs three facilities across Karnataka, producing everything from peptides to enzymes. If molecules could vote, Anthem would win by a landslide.
But there’s a twist: 70% of revenues come from just five clients. That’s not customer concentration — that’s customer dependence therapy. Add to that its Europe-heavy revenue (54.6%), and you’ve got a company that earns in euros but dreams in rupees.
Yet, Anthem’s balance sheet looks like it just came out of a detox retreat — lean debt, high cash generation, and profits growing faster than a yeast culture on steroids.
So, does the bio buzz justify the valuation? We’ll dissect it like a well-labeled DNA strand.
3. Business Model – WTF Do They Even Do?
Anthem Biosciences isn’t your average pill pusher. It’s a CRDMO — Contract Research, Development, and Manufacturing Organization — which basically means pharma companies outsource their R&D headaches to Anthem, who then turns science projects into finished drugs.
It operates across two main segments:
a) CRDMO Services – Anthem is one of the few Indian firms that can handle both small molecules (chemicals) and large molecules (biologics). They offer a buffet of services: from target identification and lead selection to pre-clinical and clinical manufacturing — everything short of administering the drug to patients.
b) Specialty Ingredients – This is the money-spinner side hustle. Anthem makes fermentation-based APIs, enzymes, probiotics, and vitamin analogues — products that end up in everything from your energy drink to your vitamin D capsule.
If the CRDMO business is their scientific symphony, specialty ingredients are the background percussion keeping profits steady.
With three facilities — Bommassandra, Harohalli Unit II, and an under-construction Unit III — Anthem’s total custom synthesis capacity will soon exceed ~670 kL, alongside fermentation capacity of ~182 kL. Translation: they’re brewing more than your neighborhood craft beer brand.
4. Financials Overview
Metric (₹ Cr)
Q2FY26
Q2FY25
Q1FY26
YoY %
QoQ %
Revenue
550
525
540
4.8%
1.9%
EBITDA
218
195
191
11.8%
14.1%
PAT
173
162
136
6.8%
27.2%
EPS (₹)
3.09
2.90
2.42
6.6%
27.7%
Annualised EPS = 3.09 × 4 = ₹12.36 At CMP ₹697 → P/E ≈ 56.4 (not bad for a company priced at 84x TTM, market still catching up).
Commentary: Revenue is growing like a disciplined child — small steps, no tantrums. EBITDA margin at 40% is elite, and PAT jumped 27% QoQ like it just had a Red Bull. If Anthem maintains this rhythm, it might just become India’s next biotech bluechip.
5. Valuation Discussion – Fair Value Range Only
Let’s sanity-check Anthem’s ₹697 party price.
a) P/E Method:
Annualised EPS: ₹12.36
Reasonable Biotech P/E Range: 40x–60x → Fair Value Range = ₹494 – ₹742
b) EV/EBITDA Method:
EBITDA (FY25): ₹672 Cr
EV/EBITDA peers average: 25x–35x → Fair EV Range = ₹16,800 – ₹23,500 Cr Subtract Net Debt (~₹113 Cr – cash rich): negligible → Fair Value per share ≈ ₹598 – ₹837
c) DCF (Simplified): Assume 20% earnings growth next 5 years, terminal growth 5%, discount 12% → ₹620 – ₹800
🎯 Fair Value Range (Educational): ₹600 – ₹800
This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
IPO & Listing (July 2025): Anthem raised ₹33,950 million (~₹3,395 crore) and made a smashing debut. Within months, it’s already in the CRDMO hall of fame.
